Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 15, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation and Characterization of CAR-T Cells.

Sarah Ash1, Greta Maria Paola Giordano Attianese1, Paris Kosti1

  • 1Department of Fundamental Oncology, Ludwig Institute for Cancer Research Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Methods in Molecular Biology (Clifton, N.J.)
|May 13, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: High-titer modular retroviral vectors enabled by an antisense cassette design preventing dsRNA formation during virus production.

Molecular therapy. Advances·2026
Same author

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026
Same author

Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial.

European journal of endocrinology·2026
Same author

High-titer modular retroviral vectors enabled by an antisense cassette design preventing dsRNA formation during virus production.

Molecular therapy. Advances·2026
Same author

Effect of vosoritide on spine morphology in children with achondroplasia: 1-year results from a randomized phase 2 study.

Journal of the Endocrine Society·2026
Same author

Effect of vosoritide on genu varum in children with achondroplasia after 1 year in randomized placebo-controlled trials.

Journal of the Endocrine Society·2026

This study details protocols for engineering next-generation chimeric antigen receptor (CAR)-T cells for solid tumors. It covers lentivirus/retrovirus production, T cell manipulation, in vitro assays, and in vivo mouse models for enhanced cancer therapy.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biotechnology

Background:

  • Chimeric antigen receptors (CARs) are synthetic receptors enabling T-cell activation against specific antigens.
  • Current clinical CAR-T therapies primarily use second-generation (2G) CARs, necessitating advancements for solid tumor treatment.
  • Next-generation CAR-T cells aim to enhance function and safety, particularly for overcoming solid tumor microenvironment challenges.

Purpose of the Study:

  • To present optimized laboratory protocols for developing and evaluating advanced CAR-T cell therapies.
  • To detail methods for lentivirus and retrovirus production, T cell engineering, and characterization.
  • To provide a framework for preclinical assessment of CAR-T cells in solid tumor models.

Main Methods:

  • Development of switchable CARs for remote control of T cell activity.
Keywords:
Adoptive cell transfer (ACT)CancerChimeric antigen receptor (CAR)Gene engineeringImmunotherapyLentivirusRetrovirusSolid tumorTransduction

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells
06:22

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells

Published on: February 2, 2024

Related Experiment Videos

Last Updated: May 15, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells
06:22

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells

Published on: February 2, 2024

  • Implementation of non-viral (CRISPR/Cas9, base editing, transposons) and viral (lentivirus, retrovirus) gene-editing tools.
  • Establishment of protocols for CAR-T cell production, purification, activation, transduction, expansion, and in vitro/in vivo assays.

    • Main Results:

    • Detailed protocols for lentivirus and retrovirus production and titration are provided.
    • Methods for purification, activation, transduction, and expansion of mouse and human CAR-T cells are described.
    • In vitro assays for assessing CAR-T cell efficacy (transduction, proliferation, cytotoxicity) and in vivo study designs are presented.

    Conclusions:

    • The presented protocols facilitate the development and preclinical evaluation of enhanced CAR-T cells for solid tumor treatment.
    • These methods are adaptable for T cell receptor (TCR)-engineered T cells.
    • The protocols support comprehensive analysis from CAR-T cell production to in vivo efficacy studies.